18
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Optineurin Gene Expression Level in Human Trabecular Meshwork Does Not Change in Response to Pressure Elevation

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mutations in the gene optineurin (OPTN) have been associated with primary-open angle glaucoma. Here we present a study on the level of OPTN gene expression in the human trabecular meshwork in response to increased perfusion pressure in the anterior chamber perfusion model of the human eye. Perfusion pressure was raised from 10 to 30 mm Hg for periods ranging between 1 and 24 h. OPTN transcript levels in the trabecular meshwork were determined using real-time quantitative polymerase chain reaction. The results show no statistically significant alteration of the OPTN transcript level after raising the pressure. Moreover, no changes were detected in the transcript levels of the 3 known OPTN isoforms. This result shows that enhanced pressure levels do not lead to rapid changes in gene expression levels of OPTN in human trabecular meshwork. This suggests that alterations in OPTN gene expression are not involved in the mechanisms regulating aqueous humor outflow after an increase in intraocular eye pressure.

          Related collections

          Most cited references1

          • Record: found
          • Abstract: found
          • Article: not found

          Glaucoma.

          In 2000 an estimated 66.8 million people worldwide will have glaucoma, 6.7 million of whom will be bilaterally blind from irreversible optic-nerve damage. Yet even in developed countries with public educational programmes that target glaucoma, half of the individuals with glaucoma remain undiagnosed. Patients with even mild visual impairment secondary to glaucoma may have difficulties with mobility, driving, and social interactions. Although glaucoma may be associated with increased eye pressures, its diagnosis does not rely on a specific level of eye pressure. Diagnosis of glaucoma often relies on examination of the optic disc and assessment of the visual field. The two most common types of glaucoma--primary open-angle glaucoma and primary angle-closure glaucoma--have different risk factors. Although similar medications can be used to treat these two types of glaucoma, the overall management of patients differs in important ways. Until recently, there were no randomised clinical trials that showed the effectiveness of lowering eye pressures with medications or surgery in patients with glaucoma. However, in 1998 a randomised clinical trial showed the benefit of lowering eye pressure in patients with glaucoma who had eye pressures of 24 mm Hg or less. Because glaucoma is treatable, and because the visual impairment from glaucoma is irreversible, early detection of the disease is critically important.
            Bookmark

            Author and article information

            Journal
            ORE
            Ophthalmic Res
            10.1159/issn.0030-3747
            Ophthalmic Research
            S. Karger AG
            0030-3747
            1423-0259
            2003
            April 2003
            24 March 2003
            : 35
            : 2
            : 93-96
            Affiliations
            Netherlands Ophthalmic Research Institute–KNAW, Glaucoma Research Group, Amsterdam, The Netherlands
            Article
            69133 Ophthalmic Res 2003;35:93–96
            10.1159/000069133
            12646749
            c9d29289-9870-4067-b8e6-38656c4de528
            © 2003 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            History
            : 24 August 2002
            : 02 December 2002
            Page count
            Figures: 2, Tables: 1, References: 14, Pages: 4
            Categories
            Original Paper

            Vision sciences,Ophthalmology & Optometry,Pathology
            Gene expression,Anterior segment perfusion,Optineurin,Trabecular meshwork,Glaucoma,Quantitative real-time PCR,Intraocular eye pressure,Aqueous outflow

            Comments

            Comment on this article